Abstract:Abstract Background RBM10 is frequently mutated in lung adenocarcinoma (LUAD). Several studies identified RBM10 could regulate proliferation and apoptosis, but how can RBM10 mutations affect tumor microenvironment (TME) is elusive. We aimed to explore the effect of RBM10 mutations on TME. Methods Whole-exome sequencing (WES) was performed on 39 treatment-naïve early-stage LUADs presenting as ground-glass nodules (GGN). Data from TCGA database (n=562) and WES and RNA-sequencing (RNA-seq) data of another Chinese LUAD cohort (n=128, CHOICE_ADC cohort) were obtained. GSEA was performed to determine immune related pathways. Single-sample GSEA (ssGSEA), CIBERSORT and TIMER were used to evaluate immune infiltration. TIDE was used to calculate the predictive immunotherapy response. Results RBM10 mutational frequency in TCGA and CHOICE_ADC cohort were 7% and 8%, but reached 28% in GGN cohort. Because there were more early-stage LUADs in our cohort, RBM10 more likely mutated in early-stage LUAD. Additionally, majority of RBM10 mutations were protein-truncating variants, including nonsense and frameshift mutation. Survival analysis revealed RBM10 deficiency was related to shorter overall survival. GSEA was performed using RNA-seq data from TCGA and CHIOCE_ADC cohort and revealed immune related pathways were enriched in RBM10 deficient population. In TCGA cohort, the inflammatory response and TGF-β signaling were two of the representative enriched pathways. Similarly, the interferon-γ response and TNF-α signaling via NF-κB were two of the most enriched pathways in CHOICE_ADC cohort. The number of neoantigen and tumor mutation burden were higher in patients with RBM10 mutations. We further compared HLA expression between patients with RBM 10 mutations and wild-type population and found numerous HLAs showed higher expression in RBM10 deficient population, such as HLA.DRB6, HLA.DRB5 and HLA.DQA1. By using ssGSEA, we found diverse immune signatures (Th1 cells, macrophages, DC and CD8+T cells) showed higher enrichment levels in population with low RBM10 expression in both TCGA and CHOICE_ADC cohort. Similarly, RBM10 expression had a positive correlation with the levels of myeloid dendritic cell, macrophage, neutrophil, CD8+T cell and CD4+T cell according to the results of TIMMER and CIBERSORT. Finally, we found PD-L1 and TIM3 exhibited higher expression in population with RBM10 deficiency. Additionally, the predicted immunotherapy response was calculated through TIDE algorithm. Expression of IFNG was upregulated and immune evasion level was lower in population with RBM10 deficiency. Conclusion RBM10 mutations were more common in early-stage LUADs. Immune activity in patients with RBM10 mutations was elevated and there were more neoantigens in these patients. Our results demonstrated that LUAD patients with RBM10 mutations could more likely benefit from immunotherapy. Citation Format: Bing Liu, Yang Chen, Nan Wu. RBM10 mutations remodel tumor microenvironment of lung adenocarcinoma and contribute to its progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2822.

RBM10 Inhibits Cell Proliferation of Lung Adenocarcinoma Via RAP1/AKT/CREB Signalling Pathway.

RBM10 Regulates Tumor Apoptosis, Proliferation, and Metastasis

Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD)

RBM10 recruits METTL3 to induce N6-methyladenosine-MALAT1-dependent modification, inhibiting the invasion and migration of NSCLC

RBM10 regulates the tumorigenic potential of human cancer cells by modulating PPM1B and YBX1 activities

RBM10 Modulates Apoptosis and Influences TNF-α Gene Expression.

The role of RBM10 mutations in the development, treatment, and prognosis of lung adenocarcinoma

RBM15 Promotes Hepatocellular Carcinoma Progression by Regulating N6-methyladenosine Modification of YES1 Mrna in an IGF2BP1-dependent Manner.

The Human RNA Binding Motif Protein RBM10 Modulates Apoptosis by Influencing Tumour Necrosis Factor Expression

RNA-binding motif protein 10 inactivates c-Myc by partnering with ribosomal proteins uL18 and uL5

A Gene Mutation in RNA-binding Protein 10 is Associated with Lung Adenocarcinoma Progression and Poor Prognosis.

Histone Demethylase RBP2 Promotes Lung Tumorigenesis and Cancer Metastasis.

RBM5 suppresses proliferation, metastasis and glycolysis of colorectal cancer cells via stabilizing phosphatase and tensin homolog mRNA

The tumor suppressor gene RBM5 inhibits lung adenocarcinoma cell growth and induces apoptosis

RBM10 Loss Promotes EGFR-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition.

N6-Methyladenosine Methylation Regulator RBM15 is a Potential Prognostic Biomarker and Promotes Cell Proliferation in Pancreatic Adenocarcinoma

RNA Binding Motif Protein 10 Suppresses Lung Cancer Progression by Controlling Alternative Splicing of Eukaryotic Translation Initiation Factor 4H

Expression of RNA-binding Motif 10 is Associated with Advanced Tumor Stage and Malignant Behaviors of Lung Adenocarcinoma Cancer Cells

Rpn10 promotes tumor progression by regulating hypoxia-inducible factor 1 alpha through the PTEN/Akt signaling pathway in hepatocellular carcinoma.

Rbm10 Mutations Remodel Tumor Microenvironment Of Lung Adenocarcinoma And Contribute To Its Progression.

RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma